Katherine E. Talcott

Dr. Katherine E. Talcott


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2024 in Neurology
Verified
Journal Article
Closed access
JSJacqueline K. Shaia
Jacqueline K. Shaia
NSNeha Sharma
Neha Sharma
MKMadhukar Kumar
Madhukar Kumar
JCJeffrey Chu
Jeffrey Chu
CMChristopher Maatouk
Christopher Maatouk
DCDevon A. Cohen
Devon A. Cohen
With the obesity epidemic within the United States, the prevalence of idiopathic intracranial hypertension (IIH) is predicted to rise. IIH prevalence and racial disparities have rarely been reported in the United States. The purpose of this study was to evaluate the prevalence of IIH in a large national database while stratifying by sex, age, race, and ethnicity. This was a cross-sectional epidemiologic evaluation conducted in the TriNetX US Collaborative network using data from 2015 to 2022. Patients with an International Classification of Diseases code of IIH and papilledema or unspecified papilledema were included in the study. Any secondary cause of intracranial hypertension including cerebral neoplasms and hydrocephalus were excluded from the study. IIH trends were later compared with TriNetX cohort obesity trends. Prevalence and prevalence odds ratios (ORs) were calculated in Microsoft Excel and R Studio. Among 85 million patients in this database, a 1.35 times increase in the prevalence of IIH occurred between 2015 and 2022 from 7.3 (95% CI 6.9-7.7) individuals per 100,000 to 9.9 (95% CI 9.5-10.3) individuals per 100,000 in 2022. In 2022, Black female individuals had the highest prevalence of IIH with 22.7 individuals per 100,000 compared with the 13.7 White female individuals per 100,000. Patients aged 11-17 years showed the largest growth of IIH prevalence with female individuals increasing by 10 individuals per 100,000 by 2022. Overall, Black and Hispanic patients had the largest prevalence OR of IIH at 1.66 (95% CI 1.49-1.85) and 1.33 (95% CI 1.14-1.56), respectively, compared with White female patients. IIH is a rapidly increasing health care concern for the US population, particularly among adolescent patients. Black and Hispanic female individuals are most predominately affected by this incapacitating disorder.

4 February 2024 in Ophthalmology Retina
Verified
Journal Article
Closed access
PSPriya Shukla
Priya Shukla
MRMatthew W. Russell
Matthew W. Russell
JMJustin C. Muste
Justin C. Muste
JSJacqueline K. Shaia
Jacqueline K. Shaia
MKMadhukar Kumar
Madhukar Kumar
KTKatherine E. Talcott
Katherine E. Talcott

6 March 2024 in Eye
Verified
Journal Article
Open access
PDF file
CPCarter J. Payne
Carter J. Payne
UGUrvi Gupta
Urvi Gupta
CMChristopher M. Maatouk
Christopher M. Maatouk
BKBlanche L. Kuo
Blanche L. Kuo
SPScott Perkins
Scott Perkins
KTKatherine E. Talcott
Katherine E. Talcott
Background and objective: Anti-vascular endothelial growth factor (VEGF) injections are often administered less frequently in real-world treatment of diabetic macular oedema (DMO) than what was studied in clinical trials. This study aims to characterise real-world DMO treatment patterns and the effect of treatment intervals on patient outcomes. Study design/patients and methods: This was a retrospective study of 291 patients with DMO treated with anti-VEGF therapy. 12- and 24-month best visual acuity (BVA) and central subfield thickness (CST) were compared between injection interval groups, which were determined by averaging the two most recent injection intervals. Multiple linear regressions were performed to identify factors associated with injection interval, BVA, and CST. Results: 48.8% of patients received injections less than or equal to every 8 weeks (≤ q8w), 27.5% between every 8 to 12 weeks (q8–12w), and 23.7% greater than every 12 weeks (> q12w). Baseline CST was similar (p = 0.32), but BVA differed significantly in q8–12w patients (p = 0.0095). BVA and CST at 12 months were similar, but q8–12w patients experienced greater 12-month BVA improvement (7.36 ± 12.4 letters) than > q12w patients (1.26 ± 12.3 letters; p = 0.0056). 24-month BVA and CST changes were similar between groups (p = 0.30 and 0.87). Baseline BVA, HbA1c, and sex were associated with 12-month BVA, and baseline BVA and CST were associated with 12-month CST. Conclusion: Many patients experienced improvements in BVA and CST over 12 months of treatment despite receiving less frequent anti-VEGF therapy than recommended in the pivotal trials. The present study showed that extended treatment intervals with bevacizumab were effective in preserving vision of many individuals with high baseline BVA.

1 September 2021 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
CRChandruganesh Rasendran
Chandruganesh Rasendran
YIYahya Imran
Yahya Imran
KTKatherine E. Talcott
Katherine E. Talcott

7 February 2023 in Eye
Verified
Journal Article
Open access
PDF file
ABAbhinav R. Bheemidi
Abhinav R. Bheemidi
RKRoshni Kailar
Roshni Kailar
CVCarolina C. S. Valentim
Carolina C. S. Valentim
AKAneesha Kalur
Aneesha Kalur
RSRishi P. Singh
Rishi P. Singh
KTKatherine E. Talcott
Katherine E. Talcott
Objectives To determine the baseline risk factors for elective ophthalmic surgery cancellations and characterise the reasons for cancellation. Methods This is a retrospective, non-randomised study performed at a large tertiary ophthalmic centre. It included a consecutive sample of patients above the age of 18 who had an ophthalmic surgery scheduled at Cole Eye Institute, Cleveland Clinic, OH between January 2012 and December 2019. An automated search pull identified 75,908 scheduled surgeries (63,987 completed and 11,921 cancelled surgeries). Statistical analysis was performed using R (version 3.5.1). Main outcome measures were baseline factors that impact risk for surgery cancellation and reasons for surgery cancellation. Results Analysis was performed on 69,963 scheduled surgeries (57.37% Female, 42.63% Male; Mean age of 62.72 years; 59,959 completed and 10,004 cancelled surgeries). Of the 2384 cancelled surgeries with reasons provided, the most common causes of cancellation were patient refusal (38.42%), patient health condition (18.79%), and rescheduling of surgery (15.27%). Female sex, black race, patient age less than 50 years, non-cataract surgeries, regional mean household income greater than $82,900, Medicare insurance, and geographical distance of less than 10 miles from home to the surgery site were each associated with a significantly increased risk of surgery cancellation (p < 0.01). Conclusions This study successfully identified several baseline factors predicting elective ophthalmic surgery cancellation. The clinical insights gained from these lines of enquiry may be used to construct models that not only identify patients at greater risk for cancellation but also highlight which interventions have greatest efficacy in preventing ophthalmic surgery cancellations.

17 February 2021 in Canadian Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
ACAndrew X. Chen
Andrew X. Chen
AHAlexander Haueisen
Alexander Haueisen
CRChandruganesh Rasendran
Chandruganesh Rasendran
GHGrant L. Hom
Grant L. Hom
TCThais F. Conti
Thais F. Conti
KTKatherine E. Talcott
Katherine E. Talcott